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Background: Retroperitoneal sarcomas (RPS), such as pleomorphic leiomyosarcoma, often invade or displace vital
organs in the abdominal cavity and exhibit an aggressive clinical course. Complete surgical resection of the tumor
and preoperative radiotherapy and chemotherapies can be used for non-metastatic RPS. However, in case of huge
retroperitoneal sarcoma fully occupying the abdominal cavity, surgical resection tends to be insufficient, resulting in
poor outcomes. This report describes a case of rapidly progressive retroperitoneal pleomorphic leiomyosarcoma
that was favorably controlled by debulking surgery followed by combination chemotherapy and radiotherapy.
Case presentation: A 65-year-old Japanese woman developed abdominal discomfort due to a huge retroperitoneal
tumor fully occupying the abdominal cavity. The immunohistochemical diagnosis was pleomorphic leiomyosarcoma
with high-grade malignancy and aggressive proliferative features. Debulking surgery could be performed, but the small
residual tumor had rapidly grown to an approximately 22 cm in length on the major axis within 38 days after the
operation. The patient’s general condition progressively declined. Combination chemotherapy, consisting of
doxorubicin and ifosfamide, was successfully administered for six cycles while maintaining dose intensity. The best
objective response was a partial response, and the chemotherapy was well tolerated. Approximately 50 Gy of
radiotherapy was delivered to the remaining tumor. This multimodal strategy resulted in progression-free survival
for more than 17 months and achieved sustained symptomatic relief.
Conclusions: Multimodal therapy with debulking surgery, combination chemotherapy and radiotherapy
controlled a rapidly progressive retroperitoneal pleomorphic leiomyosarcoma. Maintaining dose intensity of the
chemotherapy and radiotherapy might contribute to overall tumor control.
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Soft tissue sarcomas (STS) are malignant tumors that arise
from mesoderm-derived tissues, such as fat, muscle, and
connective tissue. Approximately 15% of cases of STS
occur in the retroperitoneum. Since retroperitoneal sarco-
mas (RPS) are often asymptomatic until they become large
and are located adjacent to vital organs and structures
(e.g., the aorta, inferior vena cava, duodenum, and head of
the pancreas), appropriate surgical resection with negative* Correspondence: keitauch@kyumed.jp
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unless otherwise stated.microscopic margins (R0 resection) is sometimes difficult
to achieve. Furthermore, even after curative resection is
achieved, more than half of RPS patients develop local
recurrence, which is the leading cause of death [1,2]. Multi-
modal therapy incorporating surgery, radiotherapy, and
chemotherapy is thus expected to improve survival in pa-
tients with RPS. We treated an RPS patient with rapidly
progressive features of pleomorphic leiomyosarcoma (PLS)
using combined modalities and achieved relatively long-
term disease control.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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A 65-year-old Japanese female presented to our department
with abdominal discomfort. Computed tomography (CT)
revealed a 30 × 23 × 15 cm tumor in the right retroperito-
neum, compressing the inferior vena cava (Figure 1a). The
patient had no relevant personal or family history. La-
boratory blood testing showed no major signs of organ
dysfunction, except for increased levels of aspartate ami-
notransferase (AST), alanine aminotransferase (ALP), and
γ-glutamyltranspeptidase (γ-GTP). Preoperative radiother-
apy was not administered because a large treatment vol-
ume could otherwise lead to late radiation-related damage
of critical organs, such as the kidneys, liver and small
bowel and because the patient required a therapeutic strat-
egy that would produce more rapid relief of symptoms.
Surgical resection for the purpose of tumor debulking was
then performed. A small tumor beside the anterior aspect
of the inferior vena cava and on the uncinate process of
the pancreas that was approximately 2 cm in length on
the major axis remained. Immunohistochemical analysis
revealed high-grade malignant cells strongly positive for
h-caldesmon and positive for α-smooth muscle actin,a
c
Figure 1 Computed tomography scan of the abdominal tumor. (a) Co
CT scan obtained before the operation reveals a bulky 30 × 23 × 15 cm ma
the liver to the pelvis. The tumor contained a clustered contrast-filled bulkh
debulking surgery. At 38 days after successfully performed debulking surge
rapidly, returning to the size of the tumor observed before surgery. (c) CT
response to five cycles of chemotherapy with doxorubicin and ifosfamide.
following the completion of radiation therapy.desmin, and calponin, resulting in a diagnosis of PLS. A
high proliferation rate of the tumor cells was also seen on
immunohistochemical analysis (Figure 2).
During the period of her recovery from the surgery and
preparation for adjuvant radiotherapy, abdominal fullness
recurred, and a CT scan revealed that the tumor had re-
grown to 22 × 14 × 23 cm within only 38 days after the
surgery. The regrown tumor was approximately 1000-fold
higher in volume when compared with the residual tumor
(Figure 1b). On day 47 after the operation, combination
chemotherapy with doxorubicin (DXR) and ifosfamide
(IFM) was initiated. The dose administration schedule was
designed as follows: infusional DXR (30 mg/m2) on days
1–2 and IFM (2,000 mg/m2) on days 1–5 every 21 days.
The chemotherapy was administered for six cycles, and
her symptoms decreased while Eastern Cooperative On-
cology Group performance status (PS) improved by the
time of the initiation of the second cycle. The best objective
response rate was a partial response (PR, 64%; 22 × 14 ×
23 cm before chemotherapy and 8 × 8 × 13 cm after 5 cycles
of chemotherapy) according to the new response evaluation
criteria in solid tumours (RECIST) ver. 1.1 (Figure 1c).b
d
mputed tomography (CT) scan at the time of the initial patient visit. A
ss in the right retroperitoneal space, ranging from the undersurface of
ead and cyst-like structure. (b) CT scan performed at 38 days after the
ry, the formerly small residual tumor is noted to have progressed
scan after chemotherapy. CT scan shows reduction in tumor size in
(d) CT scan after radiotherapy. The residual tumor continued to shrink
Figure 2 Pathological examination of the resected tumor.
Pathological examination of the resected tumor shows multiple
nuclei in the center and abnormal mitosis in the upper right area of
this image. These findings indicate high-grade malignancy.
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AE) ver. 4 grade 4 neutropenia and grade 3 febrile neutro-
penia occurred during the first cycle. In subsequent
cycles of chemotherapy, the prophylactic administra-
tion of granulocyte-colony stimulating factor (filgras-
tim, 75 μg/day) was employed to maintain the dose
intensity of the chemotherapy. The chemotherapy was
generally well tolerated. After the fifth cycle, the tumor
remained beside the inferior vena cava, and the patient re-
ceived a conventional radiotherapy dose of 50 Gy adminis-
tered once daily (2 Gy per fraction) (Figure 1d). No serious
adverse events, such as perforation of the digestive tract,
radiation-induced enterocolitis, or hematuria, were ob-
served. Following the administration of the radiotherapy,
the patient underwent one cycle of DXR and IFM chemo-
therapy followed by single-agent chemotherapy consisting
of one cycle of DXR (60 mg/m2 on day 1) and one cycle of
IFM (2,000 mg/m2 on days 1–5) and then was observed.
More than 17 months of progression-free survival and sus-
tained symptom relief was achieved.
Discussion
Leiomyosarcomas are one of the most aggressive subtypes
of RPS. PLS was reported to account for 8.6% of all leio-
myosarcomas and exhibited an aggressive course accom-
panied by rapid local recurrence and distant metastasis [3].
A study of 23 PLS patients revealed that 65% died of the
tumor and that 48% had recurrence or metastasis. Tumors
of the PLS showed morphologically higher grade, and
higher mindbomb E3 ubiquitin protein ligase 1 (MIB-1) la-
beling index than in ordinary leiomyosarcoma patients [3].
In another analysis of 41 cases of leiomyosarcomas with
pleomorphic features, metastasis was observed in 89% of
cases, and the mortality rate was 50% at the last follow-up(range, 3–104 months; mean, 27.5 months), even though
surgical resection and perioperative therapies were per-
formed in 90% and 17%, respectively [4]. The maximum
tumor dimension in these studies ranged from 2.5 to
21.0 cm (mean, 9.8; median, 9.0 cm) [4] and from 2.0 to
18 cm (mean, 9.1; median, 9.0 cm) [3]. The histopatho-
logical findings of the present PLS case also showed high-
grade malignant and proliferating features. However,
prominent tumor growth was strikingly observed in which
approximately 2 cm of the tumor remaining after debulk-
ing surgery enlarged to 30 cm in diameter in only 38 days.
These clinical observations strongly suggested an aggres-
sive tumor course and a poor prognosis.
Radiotherapy is a promising modality for the treatment
of leiomyosarcoma [5,6]. At the time of initial diagnosis,
however, preoperative radiation was not conducted, and
the surgical resection was performed for the purpose of
quick symptom relief and conservation of organ function.
Similar to the favorable results of perioperative radiation
for sarcomas of the extremities [7,8], retrospective studies
revealed that neoadjuvant radiation therapy for RPS was
associated with favorable outcomes [9,10]. While the typ-
ical preoperative dose for sarcomas of the extremities is
50 Gy, most institutions use 45–50 Gy of radiation in the
treatment of RPS for preoperative radiotherapy. Despite the
increased prevalence of multiple risk factors, preoperative
radiation did not increase 30-day postoperative morbidity
and mortality in a retrospective study of 696 RPS patients
[11]. Although a phase III prospective study (Z9031) ad-
dressing the role of preoperative radiation for patients with
RPS did not report definitive results because of poor ac-
crual [12], another phase III study comparing surgery alone
versus perioperative radiation followed by surgery for non-
metastatic retroperitoneal sarcoma is now ongoing [13].
These studies could provide us with vital information to
help guide appropriate perioperative managements for pa-
tients with RPS.
In a retrospective analysis of 500 RPS, 185 patients
underwent complete resection and had a significant sur-
vival benefit when compared with patients with incom-
plete resection [1]. Although complete tumor resection
could not be achieved in the present case; rather, tumor
debulking was performed, adequate complete resection
of RPS is the primary goal, and the clinical benefit of
debulking surgery has not been proven.
Single-agent DXR is active in the treatment of metastatic
STS and is associated with an increased overall response
rate (ORR) [14]. While no significant improvements in over-
all survival (OS) have been reported, combination chemo-
therapy, such as DXR plus IFM, produces a favorable
response and is suggested to be used for the specific condi-
tion that tumor response might provide clinical benefit [15].
We employed combination chemotherapy and subsequent
radiotherapy (50 Gy/25 fractions) against a reduced-sized
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gression free survival for 17 months. Since the efficacy of
continuing chemotherapy until disease progression has not
been thoroughly investigated [16], considering the cumula-
tive toxicity of DXR and the late toxicity of radiation, close
follow-up was chosen in this case. In terms of radiation in
combination with chemotherapy, retrospective analysis sug-
gested that ifosfamide pulse radiation had a better outcome
than radiation alone [17].
Several new agents for STS, including leiomyosarcoma,
are under investigation. The combination of gemcitabine
and docetaxel has been shown to possess activity against
leiomyosarcoma, particularly uterine lesions (ORR, 58%)
[16,18]. Recently, pazopanib, a multi-targeted tyrosine kin-
ase inhibitor, has been reported to be effective in patients
with advanced non-adipocytic sarcoma who have a history
of prior chemotherapy. That study revealed a significant
clinical benefit in progression-free survival in favor of
pazopanib when compared with placebo, especially in the
subgroup with leiomyosarcoma: the hazard ratio was 0.31
(95% Confidence interval (CI): 0.20-0.40) and the propor-
tion of patients experiencing partial response (PR) and
stable disease (SD) was 6% and 67%, respectively [19].
Therefore, these regimens may be a treatment option for
cases similar to the present case in the future.
Since leiomyosarcomas tend to be resistant to conven-
tional chemotherapy and because varying results are seen
in each individual case [16], a universal approach has not
yet been defined. In particular, pathologically high-grade
tumors, such as PLS, are associated with a significantly
poor survival despite a relative high response rate. The use
of a multimodal approach is a promising therapeutic strat-
egy for such cases. In the present case, the use of a multi-
modal approach was successful, likely based on the
following points: quick relief of symptoms by debulking
surgery, the dose intensity of the induction chemotherapy
was maintained despite the patient’s poor general status,
and appropriate radiation therapy was administered after
chemotherapy.
Conclusions
Multimodal therapy with debulking surgery, combin-
ation chemotherapy, and radiotherapy can successfully
control rapidly progressive retroperitoneal PLS. Main-
taining dose intensity of the chemotherapy and radio-
therapy might contribute to improved tumor control.
Careful selection of therapeutic modalities is required
for each patient with PLS.
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